Physician profile
Devon Charlton
NPI 1215203443
$125,058.65
in general payments reported to CMS, 2019-2025
18 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,391 · 2020: $449 · 2021: $631 · 2022: $786 · 2023: $30K · 2024: $37K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $11K · Consulting Fee: $9,640 · Food and Beverage: $6,901 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,960.50 |
| Travel and Lodging | $11,280.23 |
| Consulting Fee | $9,640.00 |
| Food and Beverage | $6,900.92 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78,107.85 | 2020-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $38,101.30 | 2019-2025 | Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $2,600.00 | 2019 | |
| Ucb, INC. | $2,516.96 | 2025 | Bimzelx |
| Amgen INC. | $1,726.80 | 2019-2025 | Evenity, Prolia, Tavneos |
| Glaxosmithkline, LLC. | $658.29 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $345.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $251.53 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $247.76 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $156.07 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $108.12 | 2022 | |
| Janssen Scientific Affairs, LLC | $89.19 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $58.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.14 | 2021-2025 | |
| Genentech, INC. | $22.69 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $15.32 | 2019 | |
| Genentech USA, INC. | $11.08 | 2019 | |
| Swing Therapeutics, INC. | $9.93 | 2025 | Stanza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Charlton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.